Expertise in
6
conditions
Expertise in
6
conditions
Blank Cancer & Blood Disorders Center
1215 Pleasant St Ste 514, 
Des Moines, IA 

Overview

Wendy Woods is a Palliative Medicine provider in Des Moines, Iowa. Dr. Woods is highly rated in 6 conditions, according to our data. Her top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 4 peer reviewed articles and participating in 55 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Palliative Medicine

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 7 Less Insurance Carriers -

Locations

Blank Cancer & Blood Disorders Center
1215 Pleasant St Ste 514, Des Moines, IA 50309

Additional Areas of Focus

Dr. Woods has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


55 Clinical Trials

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Umbrella Long-Term Follow-Up Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
View 45 Less Clinical Trials
Similar Doctors
Sophia Kang
Expertise in
6
conditions
Psychiatry | Palliative Medicine
Expertise in
6
conditions
Psychiatry | Palliative Medicine

MercyOne Des Moines Behavioral Health Care

1111 Sixth Ave, West Building, Floor 3, 
Des Moines, IA 
 (1.1 miles away)
Languages Spoken:
English
Offers Telehealth

Sophia Kang is a Psychiatrist and a Palliative Medicine provider in Des Moines, Iowa. Dr. Kang is highly rated in 6 conditions, according to our data. Her top areas of expertise are Generalized Anxiety Disorder (GAD), Major Depression, Seasonal Affective Disorder (SAD), and Post-Traumatic Stress Disorder (PTSD).

Expertise in
0
conditions
Palliative Medicine
Expertise in
0
conditions
Palliative Medicine

Mercy Clinics

1540 High St Ste 101, 
Des Moines, IA 
 (0.7 miles away)
Languages Spoken:
English

Mark Dearden is a primary care provider, practicing in Palliative Medicine in Des Moines, Iowa. His top areas of expertise are Anemia, Alzheimer's Disease, Dysgraphia, and Hypothyroidism.

Expertise in
0
conditions
Palliative Medicine
Expertise in
0
conditions
Palliative Medicine

Greater Regional Medical Center

1700 W Townline St, 
Creston, IA 
 (52.9 miles away)
Languages Spoken:
English

Daniel Walker is a primary care provider, practicing in Palliative Medicine in Creston, Iowa. His top areas of expertise are Bronchitis, Factor 13 Deficiency, High Molecular Weight Kininogen Deficiency, and Familial Hypofibrinogenemia.

Frequently Asked Questions about Dr. Wendy Woods

How do I make an appointment with Dr. Wendy Woods?

You can book an appointment with Dr. Wendy Woods by calling their office at 515-241-6500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Wendy Woods a top-rated expert for Langerhans Cell Histiocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Wendy Woods is classified as an Advanced expert for Langerhans Cell Histiocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Wendy Woods specialize in?

While Dr. Wendy Woods is a Palliative Medicine, they have specific expertise in Langerhans Cell Histiocytosis, Reticulohistiocytoma, and Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Palliative Medicine.

Does Dr. Wendy Woods participate in research or clinical trials?

Yes. Dr. Wendy Woods has published 4 articles and abstracts on conditions like Langerhans Cell Histiocytosis. You can view a list of Dr. Wendy Woods's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Wendy Woods accept my insurance?

Dr. Wendy Woods accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 515-241-6500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Woods's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile